Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Metastatic squamous neck cancer with occult primary
Stage/Subtype:  untreated metastatic squamous neck cancer with occult primary
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 29 for your search:
Start Over
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO # 06-0509, NCT00970502
Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HPV-005, NCT02163057
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0395, NCI-2011-03782, NCT01064479
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and ovwe
Sponsor: NCI, Other
Protocol IDs: FER-HN-027, NCI-2011-00272, P30CA006927, NCT01316757
Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: HP-41372, UMGCC 0804, NCT00704041
Dose-escalation Study of Oral CX-4945
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C4-08-001, NCT00891280
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
Phase: Phase I
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000654169, UPCC-808258, 808258, NCT00984074
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10499, U1111-1116-4129, 2011-003891-35, NCT01156870
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
Phase: Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: MCC 13222, NCI-2010-02340, P30CA016059, NCT01283178
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01040, NCI-2013-01545, CDR0000737061, J11105, 9008, P30CA006973, U01CA132123, U01CA062505, U01CA069912, U01CA070095, UM1CA186644, UM1CA186686, UM1CA186690, UM1CA186691, UM1CA186717, NCT01638533
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02205, CITN11-02, U01CA154967, NCT01727076
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-A-007-13, NCT01831089
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GEN701, NCT02001623
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMP-514-01, D6020C00002 (AMP-514-01), NCT02013804
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBYL719Z2101, NCT02051751
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA186-018, NCT02110082
Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCCI-HN-13-001, NCT02110992
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-008, NCT02113878
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6050C00001, NCT02221960
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-116, NCT02282371
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14P.524, 2014-085, NCT02318771
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M14-429, 2014-003557-34, NCT02365662
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE8314, NCI-2014-02279, P30CA043703, NCT02388932
Safety Study of AMG 228 to Treat Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20140131, NCT02437916
Start Over